Boston University Clinical and Translational Science Award (CTSA) Program UL105/01/2008 - 04/30/2013 (PI of Sub-Project / SP)
PI:
David M. Center, MDNIH/National Center for Health Research Resources3UL1RR025771-04
GA45329: A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS04/17/2025 - 04/17/2037 (PI)
Genentech, Inc.
Immunogenicity of herpes zoster subunit vaccine in Ulcerative Colitis patients treated with…11/20/2018 - 09/30/2025 (PI)
Pfizer, Inc
Improving Outcomes and Reducing Disparities for patients with Inflammatory Bowel Disease through Epidemiology, enhanced Disease Management, Dissemination, and Education 02/01/2024 - 09/29/2025 (Subcontract PI)
PI:
Sharmeel K Wasan, MDUniversity of North Carolina HHS CDC1U01DP006745-01
Entyvio (velolizumab) long-term safety study04/12/2016 - 06/30/2023 (Multi-PI)
PI:
Sharmeel K Wasan, MDTakeda Pharmaceuticals
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Ind…03/31/2016 - 06/30/2023 (PI)
Celgene International II Sarl
Immunogenicity of Influenza, Pneumococcal, and Hepatitis B vaccines in Inflammatory Bowel Disease…06/19/2017 - 03/31/2023 (PI)
Takeda Pharmaceuticals
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Sev…09/22/2016 - 03/31/2022 (PI)
Celgene International II Sarl
The Safety and Effectiveness of the VaricElla zosteR Vaccine (VERVE) in Anti-TNF Users11/06/2017 - 03/31/2019 (PI)
Univ of Alabama NIH-NIAMS